Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma
Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.
Authors
- Lourdes Ruiz‐Ortega (ORCID: https://orcid.org/0000-0003-3636-3367)
- Laia Aceituno (ORCID: https://orcid.org/0000-0001-5414-2408)
- Gabriel T. Schnickel (ORCID: https://orcid.org/0000-0003-4392-2200)
- Talia B. Baker
- Ralph J. Marino (ORCID: https://orcid.org/0000-0003-2670-4113)
- Roxana Dana Bucur (ORCID: https://orcid.org/0000-0002-5074-8872)
- Carlos Moctezuma
- Catherine Demers (ORCID: https://orcid.org/0000-0001-5664-345X)
- Chinedu Nwaduru (ORCID: https://orcid.org/0000-0001-9088-6631)
- David M. Chascsa (ORCID: https://orcid.org/0000-0003-2972-6545)
- Celia Martagón
- Felipe Alconchel
- Grainne M. O'Kane
- G. Sapisochin
- F. J. Krendl
- C. Magyar
- P. Tabrizian
- A. Vogel
- B. Mínguez
- V. Banz
- K. Watt
- R. Oberhuber
Institutions
- University College Dublin (IE)
- University of Bern (CH)
- Universitat Autònoma de Barcelona (ES)
- University Health Network (CA)
- Mayo Clinic (US)
- Innsbruck Medical University (AT)
- University of Alberta (CA)
- University of San Diego (US)
- Universität Innsbruck (AT)
- University Hospital of Bern (CH)
- Huntsman Cancer Institute (US)
- Toronto General Hospital (CA)
- WinnMed (US)
- Medizinische Hochschule Hannover (DE)
- University of California San Diego (US)
- St. Vincent's University Hospital (IE)
- Mayo Clinic in Arizona (US)
- Vall d'Hebron Hospital Universitari (ES)
- Mayo Clinic Hospital (US)
- Instituto Murciano de Investigación Biosanitaria (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1111/apt.70528
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 70.15